This study suggests that the inhibition of the molecules involved in the mTORC1-HSP90-mut p53-NRF2-p62 axis could be used in combination with Apigenin to overcome the chemoresistance of pancreatic cancer cells to such treatment. The gene discussed is TP53; the disease is pancreatic neoplasm.